Alterations in cerebrospinal fluid angiotensin II by sodium intake in patients with essential hypertension. 1989

M Kawamura, and Y Kawano, and K Yoshida, and M Imanishi, and S Akabane, and Y Matsushima, and M Kuramochi, and K Shimamoto, and K Ito, and T Omae
Division of Hypertension and Nephrology, National Cardiovascular Center, Osaka, Japan.

1. Angiotensin (ANG) levels were measured in the cerebrospinal fluid of 15 patients with essential hypertension on a high sodium diet for 1 week and on a low sodium diet for a further week. ANGs were determined using a system of extraction by Sep-Pak cartridges followed by h.p.l.c. combined with radioimmunoassay. 2. Sodium depletion resulted in increases of ANG II in the cerebrospinal fluid from 1.16 +/- 0.38 (SEM) to 1.83 +/- 0.43 fmol/ml (P less than 0.01) and of ANG III from 0.65 +/- 0.11 to 0.86 +/- 0.15 fmol/ml (P less than 0.01). 3. The ANG II level in the cerebrospinal fluid was found to be unchanged and recovery of added ANG II was approximately 90%, even after incubation for 3 h, on both diets. Thus, it is unlikely that ANG II is produced or degraded in the cerebrospinal fluid in vitro. 4. There was no significant correlation between the cerebrospinal fluid and the plasma ANG II concentration on the low sodium diet. 5. These results suggest that the cerebrospinal fluid ANG II level increases with sodium depletion, and that the effect of the level of ANG II on the activity of the angiotensin-forming system in the central nervous system may be assessed by determination of ANG II in the cerebrospinal fluid in patients with essential hypertension.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010450 Endopeptidases A subclass of PEPTIDE HYDROLASES that catalyze the internal cleavage of PEPTIDES or PROTEINS. Endopeptidase,Peptide Peptidohydrolases
D012083 Renin A highly specific (Leu-Leu) endopeptidase that generates ANGIOTENSIN I from its precursor ANGIOTENSINOGEN, leading to a cascade of reactions which elevate BLOOD PRESSURE and increase sodium retention by the kidney in the RENIN-ANGIOTENSIN SYSTEM. The enzyme was formerly listed as EC 3.4.99.19. Angiotensin-Forming Enzyme,Angiotensinogenase,Big Renin,Cryorenin,Inactive Renin,Pre-Prorenin,Preprorenin,Prorenin,Angiotensin Forming Enzyme,Pre Prorenin,Renin, Big,Renin, Inactive
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine

Related Publications

M Kawamura, and Y Kawano, and K Yoshida, and M Imanishi, and S Akabane, and Y Matsushima, and M Kuramochi, and K Shimamoto, and K Ito, and T Omae
February 1953, The Journal of laboratory and clinical medicine,
M Kawamura, and Y Kawano, and K Yoshida, and M Imanishi, and S Akabane, and Y Matsushima, and M Kuramochi, and K Shimamoto, and K Ito, and T Omae
January 1984, Clinical and experimental hypertension. Part A, Theory and practice,
M Kawamura, and Y Kawano, and K Yoshida, and M Imanishi, and S Akabane, and Y Matsushima, and M Kuramochi, and K Shimamoto, and K Ito, and T Omae
August 1976, Australian and New Zealand journal of medicine,
M Kawamura, and Y Kawano, and K Yoshida, and M Imanishi, and S Akabane, and Y Matsushima, and M Kuramochi, and K Shimamoto, and K Ito, and T Omae
August 1976, Australian and New Zealand journal of medicine,
M Kawamura, and Y Kawano, and K Yoshida, and M Imanishi, and S Akabane, and Y Matsushima, and M Kuramochi, and K Shimamoto, and K Ito, and T Omae
January 1991, Life sciences,
M Kawamura, and Y Kawano, and K Yoshida, and M Imanishi, and S Akabane, and Y Matsushima, and M Kuramochi, and K Shimamoto, and K Ito, and T Omae
April 1995, Hypertension (Dallas, Tex. : 1979),
M Kawamura, and Y Kawano, and K Yoshida, and M Imanishi, and S Akabane, and Y Matsushima, and M Kuramochi, and K Shimamoto, and K Ito, and T Omae
February 1983, Nihon Jinzo Gakkai shi,
M Kawamura, and Y Kawano, and K Yoshida, and M Imanishi, and S Akabane, and Y Matsushima, and M Kuramochi, and K Shimamoto, and K Ito, and T Omae
January 1982, Hypertension (Dallas, Tex. : 1979),
M Kawamura, and Y Kawano, and K Yoshida, and M Imanishi, and S Akabane, and Y Matsushima, and M Kuramochi, and K Shimamoto, and K Ito, and T Omae
February 1977, British medical journal,
M Kawamura, and Y Kawano, and K Yoshida, and M Imanishi, and S Akabane, and Y Matsushima, and M Kuramochi, and K Shimamoto, and K Ito, and T Omae
December 1978, Clinical science and molecular medicine. Supplement,
Copied contents to your clipboard!